PBRM1 and BAP1: novel genetic mutations in malignant transformation of craniopharyngioma-a case report

被引:1
|
作者
Tamura, Mitsuru [1 ]
Yokogami, Kiyotaka [1 ]
Watanabe, Takashi [1 ]
Kawano, Tomoki [1 ]
Muta, Junichiro [1 ]
Yamashita, Shinji [1 ]
Oguri, Nobuyuki [2 ]
Sato, Yuichiro [2 ]
Takeshima, Hideo [1 ]
机构
[1] Univ Miyazaki, Fac Med, Dept Neurosurg, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan
[2] Univ Miyazaki, Univ Miyazaki Hosp, Dept Diagnost Pathol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan
关键词
Craniopharyngioma; Malignant transformation; BAP1; PBRM1; RENAL-CELL CARCINOMA;
D O I
10.1007/s10014-022-00444-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant craniopharyngioma is especially rare, so the causes and genetic mutations associated with the malignant transformation have not been explained in detail. We investigated the molecular genetic characteristics of malignant transformation in craniopharyngioma. A 53-year-old man with a history of adamantinomatous craniopharyngioma presented with complaints of subcutaneous swelling. Magnetic resonance imaging showed a less enhanced intradural supra-sellar lesion and a heterogeneously well-enhanced extradural invasive lesion infiltrating the dura mater, brain, frontal bone, and subcutaneous tissue. Histopathological examination of the recurrent tumor revealed typical findings of both craniopharyngioma (intradural supra-sellar lesion) and malignant transformation, such as marked nuclear atypia with mitosis (invasive extradural lesion), which were not present in the primary tumor. A genetic panel test with the Oncopanel system was performed to investigate the genetic mutations responsible for the malignant transformation. Four genetic mutations were identified: CTNNB1 c.C98T, TP53 p.C135fs*35(PLS = 3 UPD/LOH), PBRM1 p.R1000*(PLS = 3 UPD/LOH), and BAP1 p.L650fs*5(PLS = 3 UPD/LOH). Sanger sequencing showed CTNNB1 in both the intradural supra-sellar and extradural invasive lesions, but TP53, PBRM1, and BAP1 only in the extradural invasive lesion. The genetic mutations of PBRM1 and BAP1 may be genetic factors in the malignant transformation of adamantinomatous craniopharyngioma.
引用
收藏
页码:40 / 44
页数:5
相关论文
共 50 条
  • [21] High concordance of BAP1 and PBRM1 expression in patient-matched primary and metastatic ccRCC tumors.
    Shreders, Amanda
    Joseph, Richard Wayne
    Serie, Daniel
    Kapur, Payal
    Ho, Thai Huu
    Eckel-Passow, Jeanette
    Brugarolas, James
    Parker, Alexander S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [22] Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With PBRM1, SETD2, BAP1, or KDM5C Mutations
    Liu, Yang
    Li, Yunhao
    Xu, Haimin
    Zhou, Luting
    Yang, Xiaoqun
    Wang, Chaofu
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2023, 31 (08) : 1485 - 1494
  • [23] BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor
    Jeanette E. Eckel-Passow
    Daniel J. Serie
    John C. Cheville
    Thai H. Ho
    Payal Kapur
    James Brugarolas
    R. Houston Thompson
    Bradley C. Leibovich
    Eugene D. Kwon
    Richard W. Joseph
    Alexander S. Parker
    BMC Urology, 17
  • [24] PBRM1, SETD2 and BAP1 — the trinity of 3p in clear cell renal cell carcinoma
    Joseph Walton
    Keith Lawson
    Panagiotis Prinos
    Antonio Finelli
    Cheryl Arrowsmith
    Laurie Ailles
    Nature Reviews Urology, 2023, 20 : 96 - 115
  • [25] BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor
    Eckel-Passow, Jeanette E.
    Serie, Daniel J.
    Cheville, John C.
    Ho, Thai H.
    Kapur, Payal
    Brugarolas, James
    Thompson, R. Houston
    Leibovich, Bradley C.
    Kwon, Eugene D.
    Joseph, Richard W.
    Parker, Alexander S.
    BMC UROLOGY, 2017, 17 : 1 - 7
  • [26] Prognostic impact of concomitant loss of PBRM1 and BAP1 protein expression in early stages of clear cell renal cell carcinoma
    da Costa, Walter Henriques
    da Cunha, Isabela Werneck
    Fares, Aline Fusco
    Bezerra, Stephania M.
    Shultz, Luciana
    Clavijo, Diego Abreu
    da Silva, Deusdedit Vieira
    Netto, George Jabboure
    Guimaraes, Gustavo Cardoso
    Zequi, Stenio de Cassio
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (05) : 243.e1 - 243.e8
  • [27] Prevalence of germline BAP1 mutations in patients with malignant mesothelioma (MM)
    Hellmann, Matthew David
    Borsu, Laetitia
    Zehir, Ahmet
    Cheng, Donavan T.
    Zha, Zheng
    Siegel, Beth
    Rohrer, Rebecca W.
    Robson, Mark E.
    Arnold, Angela G.
    Fleischut, Megan Harian
    Cavatore, Magali
    Gaskeil, Alice A.
    Gawel, Craig
    Robertson, Alexander
    Viale, Agnes
    Rusch, Valerie W.
    Krug, Lee M.
    Ladanyi, Marc
    Zauderer, Marjorie Glass
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Bap1 and Pbrm1: Determinants of Tumor Grade and mTOR Activation in VHL-Deficient Mouse Models of Renal Cell Carcinoma
    Leung, Janet Y.
    Kim, William Y.
    CANCER DISCOVERY, 2017, 7 (08) : 802 - 804
  • [29] Determining the prevalence of germline BAP1 mutations in malignant mesothelioma (MM).
    Zauderer, Marjorie Glass
    DuBoff, Mariel A.
    Siegel, Beth
    Robson, Mark E.
    Arnold, Angela G.
    Berliner, Janice
    Fleischut, Megan Harlan
    Mandelker, Diana
    Ladanyi, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma
    Sneddon, Sophie
    Leon, Justine S.
    Dick, Ian M.
    Cadby, Gemma
    Olsen, Nola
    Brims, Fraser
    Allcock, Richard J. N.
    Moses, Eric K.
    Melton, Phillip E.
    de Klerk, Nicholas
    Musk, A. W.
    Robinson, Bruce W. S.
    Creaney, Jenette
    GENE, 2015, 563 (01) : 103 - 105